News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.
Algenex takes step towards commercialization of insect platform with recommendation for approval to manufacture vaccines.
Dendreon pivots to become a contract manufacturer of late-stage cell therapies, centered on its Seal Beach facility.
Catalent is to acquire German company, RheinCell Therapeutics, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.